Opinion|Videos|April 28, 2025
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
Advertisement
Video content above is prompted by the following:
- Previously, I mentioned the benefits of Lp(a) testing, even in the absence of targeted Lp(a)-lowering therapies. Let’s explore that further. How might Lp(a) testing improve overall cardiovascular risk assessment?
- How, if at all, might Lp(a) measurement influence the management of other risk factors?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
2
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
3
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
4
The Next Frontier in Hepatitis B Functional and Virologic Cure
5